Renal & Urology News just published an article saying that testosterone replacement therapy (TRT) does not make worse the oncologic outcomes for men with low testosterone and prostate cancer. The article cites the findings presented at the Canadian Urological Association meeting last week in Vancouver.
About the Study
Researchers and doctors, led by Jesse Ory of the University of British Columbia, were able to identify 83 men that had both hypogonadism (Low T) and prostate cancer. These men were administered testosterone replacement therapy. Of the group, 50 men were subject to radiation therapy, 22 underwent radical prostatectomy, 8 were places on surveillance, 1 had cryotherapy, and another was treated with high-intensity ultra sound. The average age of the patients studied was 75.5 years old. The average follow up time was forty one months.
"The investigators observed an increase in both testosterone and PSA levels in the entire cohort, but only patients with low-risk PCa had a statistically significant increase in PSA. PSA increased in the AS patients, but none of these patients were upgraded to a higher Gleason score on subsequent prostate biopsies and none have yet gone on to definitive treatment, the researchers reported. No RP patient experienced biochemical recurrence, but 3 RT patients (6%) did, as defined by 2006 Phoenix criteria (PSA nadir plus 2 ng/mL)." - Renal & Urology News
Learn more about this study and new developments by following the news from the Canadian Urological Association Meetings: http://www.renalandurologynews.com/canadian-urological-association/section/1058/